PT-141

PT-141, marketed as Vyleesi, is a synthetic cyclic seven-amino-acid analog of alpha-melanocyte-stimulating hormone. The FDA approved bremelanotide in 2019 as the first non-hormonal treatment acting centrally on hypoactive sexual desire disorder, in women who have not reached menopause — mechanically unlike either the hormonal therapies or the PDE5 inhibitors that came before it.

Where sildenafil and tadalafil act peripherally on vascular smooth muscle, this acts in the brain. It targets melanocortin receptors across the hypothalamus and limbic system to shift sexual motivation centrally, which makes it the first approved drug aimed at desire itself rather than at arousal or lubrication downstream of it.

Compounded bremelanotide is increasingly prescribed off-label to both men and women through telehealth and peptide clinics. Use in men — for low libido or difficulty with arousal — has no large randomized evidence behind it at all. That application is investigational, and it belongs with a provider who actually practices sexual medicine rather than one selling peptides.

It agonizes melanocortin receptors, binding MC4R most strongly with secondary activity at MC1R [6]. MC4R appears throughout the hypothalamus, limbic system and brainstem — the regions governing sexual motivation, reward and arousal. Switching it on is thought to lift dopamine and oxytocin signaling within the medial preoptic area, tipping the central balance toward drive.

Acting centrally is what lets it reach desire and motivation at all, rather than only the blood flow downstream, which is the whole distinction from the PDE5 drugs. Melanocortin agonists reliably produce pro-sexual behavior in animals, and what the drug does clinically in humans fits MC4R engagement [6]. The off-target activity at MC1R is not incidental: those receptors sit on melanocytes, and stimulating them repeatedly can darken patches of skin.

Two phase 3 randomized double-blind placebo-controlled trials carry the approval, both enrolling premenopausal women with generalized acquired hypoactive sexual desire disorder [1]. Each measured two co-primary endpoints — change in satisfying sexual events, and change in distress on a validated desire, arousal and orgasm scale. The drug beat placebo significantly on both, which is what makes this Grade A for the approved indication and separates it from most of what appears on this site.

A 52-week open-label extension found the benefit holding and the adverse-event profile unchanged, with nothing new emerging on safety beyond what phase 3 had already shown [2]. Subgroups specified in advance — by age, by contraception status, by baseline severity — all pointed the same direction, which supports the result generalizing rather than resting on one favorable slice [4].

A 2023 pharmacotherapy evaluation placed it in the thin landscape of treatments for female sexual dysfunction, noting that this and flibanserin both deliver modest but genuine effect sizes with different tolerability, and that patient preference and the nausea risk should drive the choice between them [5].

For men there is mechanistic rationale and small early-phase data, and no published phase 3 trial whatsoever. Off-label use in men leans on MC4R biology and clinical extrapolation. A prescriber should say that out loud before writing it, rather than letting the approval for a different population imply evidence that does not exist.

The approved regimen is a single 1.75 mg subcutaneous injection about 45 minutes before anticipated sexual activity, with a single dose the limit for any 24-hour period and the labeling capping it at eight in a month. The auto-injector goes into the abdomen or the thigh.

Compounded versions from telehealth and peptide clinics generally use the same 1.75 mg dose, usually supplied as a freeze-dried powder for reconstitution. Since compounded products are not reviewed by the FDA for equivalent potency or sterility, stick to 503B-licensed compounding pharmacies and make sure whoever prescribes it is actually monitoring you.

Nausea dominates. Across the phase 3 trials and the long-term safety program about 40% of those treated reported it, against fewer than 2% given placebo [3]. Headache and flushing turned up often too. It typically starts within an hour of injection and passes within a few hours, and pre-dosing an anti-emetic reduced the severity in practice.

Blood pressure also rises temporarily — on average about 6 mmHg systolic and 3 diastolic — within an hour, settling within twelve hours in most people [3]. That makes it contraindicated in anyone with known cardiovascular disease or uncontrolled hypertension. And repeated dosing can darken patches of the face, gums or breasts through that MC1R activity. That change may be permanent, which is a conversation to have before the first injection rather than after the tenth.